Morales L, Arenas R

Language: Spanish
References: 19
Page: 237-241
PDF size: 140.37 Kb.

ABSTRACT

Background: Scabies is a pruritic skin disorder usually generalized and mainly affecting folds and genitals and caused by Sarcoptes Scabiei var. Hominis is transmissible and of familia. Ivermectin is a semisynthetic analog of averctin used in the treatment of most of the cutaneous parasitosis. Oral ivermectine is effective and safe.
Objective: To determine the efficacy and safety of oral ivermectin in patients with scabies.
Materials and Methods: A prospective, open, longitudinal and observational study was performed in the Department of Dermatology at DR. MANUEL GEA GONZÁLEZ General Hospital, from May 2003 to August 2005. 50 patients with clinical diagnosis of scabies were included, and treated with oral ivermectin 200 mg/kg in a single dose and with one to three doses weekly. Index of cure and adverse events were recorded.
Results: Forty patients concluded the study, 12 male (30%) and 28 female (70%). The age average was of 25,8 years, with a range of 3 to 78 years. Signs and symptoms such as papules, scabs and pruritus were evaluated. Eleven patients presented complete remission with a single dose, 26 only improvement and no changes were observed in 3; with a second dose, 23 patient more presented remission; with a third dose three more patients cured and three improvement, but no remission was observed. Four patients presented transient headache.
Conclusions: Oral ivermectin is an effective and safe drug in the treatment of scabies, with a high index of remission of 92.5%.

REFERENCES

1. Huynh TH, Norman RA. Scabies and pediculosis. Dermatol Clin 2004; 22: 7-11

2. Molinaro MJ, Schwartz RA, Janniger CK. Scabies. Cutis 1995; 56: 317-321

3. Huekelbach J, Wilcke T, Winter B, Feldmeier H. Epidemiology and morbility of scabies and pediculosis capitis in resource-poor communities in Brazil. B J Dermatol 2005; 153: 150-156

4. Marcolin Magnabosco E, Devincenzi do Prado A. Factores epidemiológicos de risco associados à escabiose. An Bras Dermatol 1998; 73 (3): 239-243

5. Chosidow O. Scabies. N Engl J Med 2006; 354: 1718-1727

6. Karthikeyan K. Treatment of scabies: newer perspectives. Postgrad Med J 2005; 81: 7-11

7. Flinders DC, De Schweinitz P. Pediculosis and Scabies. Am Fam Physicians 2004; 69 (2): 341-348

8. Arenas R. Parasitosis cutáneas. Atlas de dermatología, diagnóstico y tratamiento, 3a ed, McGraw-Hill, México 2004

9. Leonard EA, Sheldon IV. Ectoparasitic Infections. Clinic in Family Practice 2005; 7: 97-104

10. Chosidow O. Scabies and pediculosis. Lancet 2000; 355: 819-826

11. Leston DM. Controversies concerning the treatment of lice and scabies. J Am Acad Dermatol 2002; 46: 794-796

12. Elgar G, MeinKing T. Ivermectin. Dermatol Clin 2003; 21-26

13. Morales C, Rodríguez M, Arenas R. Ivermectina. Revisión de su uso en escabiasis y pediculosis. Dermatología Rev Mex 2002; 46 (6): 268-272

14. Victoria J. Uso de ivermectina en niños. Dermatol Pediatr Lat 2003; 1 (1): 61-65

15. Arenas R, Ruiz Esmenjaud J, Morales CE et al. Ivermectina oral: cinco años de experiencia. Presentación de 34 parasitosis cutáneas: escabiasis, sarna costrosa, larva migrans, gnathostomiasis, pediculosis y demodecidosis. DCMQ 2003; 1 (1): 20-29

16. Macotela-Ruiz E, Méndez C, Nochebuena E. Tratamiento de escabiasis con ivermectina por vía oral en una comunidad rural cerrada. Implicaciones epidemiológicas. Dermatología Rev Mex 1996; 40 (3): 179-184

17. Macotela-Ruíz E, Peña-González G. Tratamiento de la escabiasis con ivermectina por vía oral. Gac Méd Méx 1993; 129 (3): 201-205

18. Youssef MY, Sakada HA, Eissa MM, El-Ariny AF. Topical application of ivermectin for human ectoparites. Am J Trop Med Hyg 1995; 53 (6): 652-653

19. MeinKing T, Taplin D, Hermida JL, Pardo R, Kerdel F. The treatment of scabies with ivermectin. N Engl J Med 1995; 336: 26-30